Effects of LDL and Liposomes on Drug Uptake in Lymphoma Cells
Author Information
Author(s): Koller-Lucae S K M, Schott H, Schwendener R A
Primary Institution: Department of Pathology, Division of Cancer Research, University Hospital, Zurich, Switzerland
Hypothesis
The study investigates the uptake and cytotoxic effects of N4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) mediated by low density lipoprotein (LDL) and liposomes in Daudi lymphoma cells.
Conclusion
NOAC-LDL is taken up via the LDL receptor pathway and shows different cytotoxic effects compared to liposomal NOAC.
Supporting Evidence
- NOAC-LDL binding to Daudi cells was five times higher than to human lymphocytes.
- The IC50 of NOAC-LDL was about 160 μM, while liposomal NOAC had an IC50 of 40 μM.
- Blocking LDL receptors with empty LDL protected 50% of the cells from NOAC cytotoxicity.
Takeaway
This study looks at how a special drug can get into cancer cells using fat particles called LDL, which can help deliver the medicine more effectively.
Methodology
The study compared the uptake of NOAC incorporated into LDL and liposomes in Daudi lymphoma cells and assessed cytotoxicity in vitro.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website